Tenecteplase (TNK) for ischemic stroke after 4 hours

TRACE-III trial tests benefit of later TNK, but patients didn't get thrombectomy

Tenecteplase (TNK) has become standard therapy at many centers for ischemic stroke presenting within 4.5 hours of symptom onset. TNK’s advantages over alteplase (tPA) include easier administration (single bolus dosing instead of bolus-plus-one-hour infusion), arguably superior pharmacokinetics (greater binding to fibrin), and association with improved o…